Pharmacologic management and treatment of gastroesophageal reflux disease

Diseases of the Esophagus

Volumn 17, Issue 3, 2004, Pages 197-204

  Storr, Martin ^a   Meining, A ^b  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Gastroesophageal reflux disease (GERD); Treatment

Indexed keywords

ALGINIC ACID; ANTACID AGENT; ATROPINE; CALCITONIN GENE RELATED PEPTIDE; CHOLECYSTOKININ; CIMETIDINE; CIMETROPIUM; CISAPRIDE; DOMPERIDONE; DOPAMINE; FAMOTIDINE; GASTRIN; GLUCAGON; HISTAMINE H2 RECEPTOR ANTAGONIST; METOCLOPRAMIDE; MOSAPRIDE CITRATE; NEUROTENSIN; NITRIC OXIDE; NIZATIDINE; OMEPRAZOLE; PLACEBO; PROGESTERONE; PROKINETIC AGENT; PROTON PUMP INHIBITOR; RANITIDINE; SCOPOLAMINE BUTYL BROMIDE; SECRETIN; SUCRALFATE; UNINDEXED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST; DIARRHEA; DRUG ELIMINATION; DRUG EXCRETION; DRUG MECHANISM; DRUG POTENCY; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL ENDOSCOPY; HEART ARRHYTHMIA; HEARTBURN; HOME CARE; HUMAN; LIFESTYLE; LOWER ESOPHAGUS SPHINCTER PRESSURE; MAINTENANCE THERAPY; MONITORING; PATHOPHYSIOLOGY; PH MEASUREMENT; PRIORITY JOURNAL; QT PROLONGATION; REFLUX ESOPHAGITIS; REVIEW; SYMPTOMATOLOGY; TACHYCARDIA; TORSADE DES POINTES; TREATMENT PLANNING;

GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL AGENTS; HISTAMINE AGONISTS; HOME CARE SERVICES; HUMANS; PROTON PUMPS;

EID: 5744247196     PISSN: 11208694     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2004.00408.x     Document Type: Review

References (41)

1. Locke G R, Talley N J, Fett S L et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population study in Olmsted County, Minnesota. Gastroenterology 1997; 112: 1448-56.
2. Quigley E M M. 24-hour pH monitoring for gastroesophageal reflux disease: already standard but not yet gold? Am J Gastroenterol 1992; 87: 1071-5.
3. Young M, Sanowski R, Talbert G et al. Omeprazole administration as a test for gastroesophageal reflux. Gastroenterology 1992; 102: 192.
4. Johnsson F, Weywadt I, Solhaug J et al. One-week omeprazole treatment in the diagnosis of gastro-esophageal reflux disease. Scand J Gastroenterol 1998; 33: 20.
5. Storr M, Meining A, Allescher H D. Pathophysiology and pharmacological treatment of gastroesophageal reflux disease. Dig Dis 2000; 18: 93-102.
6. Johnston B T, Collins J S, McFarland R J et al. Are esophageal symptoms reflux-related? A study of different scoring systems in a cohort of patients with heartburn. Am J Gastroenterol 1994; 89: 497-502.
7. Shi G, des Varannes S B, Scarpignato C et al. Reflux related symptoms in patients with normal esophageal exposure to acid. Gut 1995; 37: 457-64.
8. Gudmundsson K, Johnsson F, Loelsson B. The time pattern of gastroesophageal reflux. Scand J Gastroenterol 1988; 23: 75-9.
9. Meining A, Classen M. The role of diet and lifestyle measures in the pathogenesis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2000; 95: 2692-7.
10. Pehl C, Pfeiffer A, Wendl B et al. Different effects of white and red wine on lower esophageal sphincter pressure and gastroesophageal reflux. Scand J Gastroenterol 1998; 33: 118-22.
11. Kahrilas P J, Shi G, Manaka M et al. Increased frequency of transient lower esophageal sphincter relaxation induced by gastric distention in reflux patients with hiatal hernia. Gastroenterology 2000; 118: 688-95.
12. Mittal R, Holloway R, Penagini R et al. Transient lower esophageal sphincter relaxation. Gastroenterology 1995; 109: 601-10.
13. Zang Q, Lehmann A, Rigda R et al. Control of transient lower esophageal sphincter relaxations and reflux by the GABA (B) agonist baclofen in patients with gastro-oesophageal reflux disease. Gut 2002; 50: 19-24.
14. Storr M, Allescher H D. Esophageal pharmacology and treatment of primary motility disorders. Dis Esophagus 1999; 12: 241-57.
15. Dent J, Brun J, Fendrick A M et al. An evidence based appraisal of reflux disease management - the Geneval Workshop Report. Gut 1999; 44: S1-S16.
16. Albibi R, McCallum R W. Metoclopramide: pharmacology and clinical application. Ann Intern Med 1983; 98: 86-95.
17. Chiba N, De Gara C J, Wilkinson J M et al. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798-810.
18. Robertson C S, Evans D F, Ledingham S J et al. Cisapride in the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1993; 7: 181-90.
19. Rampe D, Roy M L, Dennis A et al. A mechanism for the proarrythmic effects of cisapride: high affinity blockade of the human cardiac potassium channel HERG. FEBS Lett 1997; 417: 28-32.
20. Ruth M, Hamelin B, Rohss K et al. The effect of mosapride, a novel prokinetic, on acid reflux variables in patients with gastro oesophageal reflux disease. Aliment Pharmacol Ther 1998; 12: 35-40.
21. Tytgat G N J, Nicolai J J, Reman F C. Efficacy of different doses of cimetidine in the treatment of reflux esophagitis. A review of three large, double-blind, controlled trials. Gastroenterology 1990; 99: 629-34.
22. Lambert R. Current practice and future perspectives in the management of gastroesophageal reflux disease. Aliment Pharmacol Ther 1997; 11: 651-62.
23. Bate C, Green J, Axon A et al. Omeprazole is more effective than cimetidine for the relief of all grades of GERD associated heartburn, irrespective of the presence or absence of endoscopic esophagitis. Aliment Pharmacol Ther 1997; 11: 755-63.
24. Galmiche J P, Barthelemy P, Hamelin B. Treating the symptoms of gastroesophageal reflux disease. a double-blind comparison of omeprazole and cisapride. Aliment Pharmacol Ther 1997; 11: 765-73.
25. Bate C, Keeling P, O'Morain C et al. Comparison of omeprazole and cimetidine in reflux esophagitis: symptomatic, endoscopic and histological evaluations. Gut 1990; 31: 968-72.
26. Klinkenberg-Knol E, Festen H, Jansen J et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994; 121: 161-7.
27. Vigneri G, Termini R, Pilotto A et al. A comparison of five maintenance therapies for reflux esophagitis. N Engl J Medical 1995; 333: 1106-10.
28. Richter J E. Long-term management of gastroesophageal reflux disease and it's complications. Am J Gastroenterol 1997; 92: 30-4.
29. Beck I, Champion M, Lemire S et al. The second Canadian consensus conference on the management of patients with gastroesophageal reflux disease. Can J Gastroenterol 1997; 11: 7-20.
30. Nandurkar S, Talley N J. Epidemiology and natural history of reflux disease. Baillieres Best Pract Res Clin Gastroenterol 2000; 14: 743-57.
31. Schindlbeck N E, Klauser A G, Voderholzer W A et al. Empiric therapy for gastroesophageal reflux disease. Arch Intern Med 1995; 155: 1808-12.
32. Lind T, Havelund T, Carlsson R et al. Heartburn without esophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997; 32: 974-9.
33. DeVault K R, Castell D O. ACG treatment guideline. updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 1999; 94: 1434-42.
34. Carlsson R, Galmiche J-P, Dent J et al. Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials. Aliment Pharmacol Ther 1997; 11: 473-82.
35. Storr M, Meining A, Allescher H D. Pharmacoeconomic issues of the therapy of gastroesophageal reflux disease. Exp Opin Pharmacother 2001; 2: 1099-108.
36. Bate C M, Richardson P D I. A one year model for the cost-effectiveness of treating reflux esophagitis. Br J Medicalecon 1992; 2: 5-11.
37. Fennerty M B. The economics of therapy of gastroesophageal reflux disease. Gastroenterol Int 1997; 10: 126-30.
38. Bate C M, Richardson P D I. Cost effectiveness of 20 mg and 40 mg omeprazole in oesophageal reflux disease. Br J Medicalecon 1993; 6: 59-66.
39. Tytgat G N J. Long-term therapy for reflux esophagitis. N Engl J Medical 1995; 333: 1148-50.
40. Harris R A, Kuppermann M, Richter J E. Prevention of recurrences of erosive esophagitis: a cost-effectiveness analysis of maintenance proton pump inhibition. Am J Medical 1997; 102: 78-88.
41. 2-receptor antagonists in treating patients with peptic stricture and esophagitis. Gastroenterology 1994; 106: 907-15.